Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma
DOI:
https://doi.org/10.15419/bmrat.v10i5.809Keywords:
Glioblastoma, Pembrolizumab, Anti-PD-1 immunotherapy, Immune checkpointAbstract
Background: Glioblastoma is a grade IV glioma tumor, and is the most frequent neoplasia in the central nervous system. Patients with glioblastoma have a very low overall survival rate and poor prognosis. Their major therapeutic challenges are the limited penetration of therapeutic agents through the blood-brain barrier, increased treatment resistance, and tumor heterogeneity.
Case presentation: Anti-programmed cell death 1 (PD-1) immune checkpoint blockade-based therapy using pembrolizumab achieved good stability and non-recurrence in a Kurdish patient with highgrade glioblastoma who was refractory to first-line therapy.
Conclusion: It appears that after the failure of routine and standard treatments in patients with glioblastoma, an immunotherapy-based therapeutic strategy is suitable for improving their clinical outcomes and creating antitumor effects.
Published
Issue
Section
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
